Selvax, founded in 1987, is focused on developing novel immunotherapy solutions with applications in both human and veterinary oncology
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
Week-long Fire Safety Week 2026 campaign focuses on strengthening fire prevention, preparedness, audits, and emergency response across hospitals and healthcare facilities
The company’s Growth Portfolio delivered $6.2 billion in revenue
Lifts full-year outlook as obesity drug boom accelerates
The move puts a spotlight on one of psychiatry’s most persistent clinical challenges: misdiagnosis and delay
Stroke is the second-leading cause of death and the third-leading cause of disability worldwide
The company posted revenue of €1,267 million, up 6% on a constant currency basis
But acquisition charges drag earnings into loss
The company posted revenue of Rs. 703 crore in Q4 FY26
Subscribe To Our Newsletter & Stay Updated
